Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

The big drugmaker missed analysts' revenue and earnings estimates due to one primary reason.

What's Behind Novartis' Disappointing Q2 Results

Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.

Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss

Novartis stock slipped in pre-market trading Tuesday after the drugmaker posted second-quarter sales that fell vs. a year-ago and missed analyst estimates, due to the coronavirus pandemic.

Novartis Stock Slips After Sales Miss Views On Coronavirus Impact

Novartis AG (SWX: NOVN) announced a significant decline in its sales and net profit in the second quarter on Tuesday. The company said that medicine stockpiling that was at its peak in the first quarter was largely reversed in Q2.

Novartis AG reports a 4% decline in net profit in the second quarter

Swiss drugmaker Novartis lowered its 2020 sales outlook on Tuesday after second quarter sales and profit fell, as hospitals that stocked up on medicines during the first-quarter due to the COVID-19 pandemic slowed purchases.

Novartis tightens outlook as second-quarter sales, profit fall

Basel, July 21, 2020 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said:  

Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

Basel, July 16, 2020 — Today, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can lead to death in some people, putting immense strain on fragile healthcare systems.

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.

Novartis Gets EC Approval for Enerzair Breezhaler for Asthma

T-Mobile US

Continental Resources

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Notable Insider Buys: Novartis, T-Mobile And More

The United States Department of Justice announced late on Wednesday that Novartis AG (ETR: NOT) will pay over £583.54 million to settle charges by the U.S. government that the Swiss drugmaker made illicit payments to patients and doctors in an unlawful attempt to push drug sales.

Novartis to pay over £583 million to settle U.S. charges of illicit incentives to doctors and patients

Novartis agreed to pay more than $729 million to settle U.S. government charges it paid illegal kickbacks to doctors and patients to boost drug sales, the U.S.

Novartis pays $729 million to settle U.S. kickback charges

Novartis AG (NYSE: NVS) has reached a $678 million settlement in a civil fraud lawsuit that alleged the company bribed doctors at speaker events it organized.

Novartis Settles $678M Fraud Lawsuit Alleging It Bribed Doctors At Company Speaker Events

Novartis AG has agreed to pay $678 million to settle a civil fraud lawsuit in which the U.S. government accused the Swiss drugmaker of illegally providing doctors with cash payments and other perks to induce them to prescribe its cardiovascular and diabetes drugs.

Novartis reaches $678 million settlement of U.S. fraud lawsuit

NEW YORK, June 30, 2020 /PRNewswire/ --Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG ("Novartis" or "the Company") (NYSE: NVS). Investors who purchased Novartis securities are encouraged to obtain...

NVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG and Encourages Investors to Contact the Firm

AbbVie

Amgen

AstraZeneca

Bristol-Myers

Eli Lilly

Pfizer

The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

Canada federal court dismisses drugmakers' plea challenging drug price rules

Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.

Novartis Gets Positive CHMP View for Cosentyx Label Expansion

Takeda Pharmaceutical

Swedish drugmaker, Novartis (SWX: NOVN), said last week that it will no longer seek European approval for Xiidra (dry-eye drug). According to Takeda Pharmaceutical (TYO: 4502), Novartis decision is expected to result in a £162.50 million of operating loss for the Japanese multinational pharmaceutical company.

Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra

Takeda Pharmaceutical Co Ltd said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.

Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders. On June 25, 2020, the Company agreed to pay $225 million in criminal fines and disgorge $112 million in settling bribery allegations brought forth by the U.S. Department of Justice and th

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS

Swiss drugmaker Novartis , fresh from settling U.S. charges over alleged kickbacks to doctors, is preparing for a key meeting next week with U.S.

Novartis faces key meeting in U.S. bribery scandal after settling corruption case

Swiss drug company Novartis AG NVS, +0.90% has settled with the U.S. Department of Justice and the Securities and Exchange Commission on charges made under the Foreign Corrupt Practices Act (FCPA) relating to the company and certain subsidiaries.

UPDATE: Swiss drug company Novartis settles with DoJ, SEC in case brought under Foreign Corrupt Practices Act

Novartis AG and a former unit will pay more than $346 million to resolve U.S. criminal and civil charges they bribed doctors, hospitals and clinics to prescribe their drugs and use their surgical products, U.S.

Novartis, former unit to pay $346 million to resolve U.S. bribery charges

Swiss drug company Novartis AG NVS, +0.68% has settled with the U.S. Department of Justice and the Securities and Exchange Commission on charges made under the Foreign Corrupt Practices Act relating to the company and certain subsidiaries.

Swiss drug company Novartis settles with DoJ, SEC in case brought under Foreign Corrupt Practices Act

The move hastens the demise of the malaria drug as a potential treatment for the disease.

Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

News for Novartis Stock (NVS)